Literature DB >> 36258038

Activation of homology-directed DNA repair plays key role in CRISPR-mediated genome correction.

Gourish Mondal1, Caitlin J VanLith1, Clara T Nicolas1,2, Whitney S Thompson3, William S Cao1, Lori Hillin1, Benjamin J Haugo1, Daniel R O' Brien4, Jean-Pierre Kocher4, Robert A Kaiser1,5, Joseph B Lillegard6,7,8.   

Abstract

Gene editing for the cure of inborn errors of metabolism (IEMs) has been limited by inefficiency of adult hepatocyte targeting. Here, we demonstrate that in utero CRISPR/Cas9-mediated gene editing in a mouse model of hereditary tyrosinemia type 1 provides stable cure of the disease. Following this, we performed an extensive gene expression analysis to explore the inherent characteristics of fetal/neonatal hepatocytes that make them more susceptible to efficient gene editing than adult hepatocytes. We showed that fetal and neonatal livers are comprised of proliferative hepatocytes with abundant expression of genes involved in homology-directed repair (HDR) of DNA double-strand breaks (DSBs), key for efficient gene editing by CRISPR/Cas9. We demonstrated the same is true of hepatocytes after undergoing a regenerative stimulus (partial hepatectomy), where post-hepatectomy cells show a higher efficiency of HDR and correction. Specifically, we demonstrated that HDR-related genome correction is most effective in the replicative phase, or S-phase, of an actively proliferating cell. In conclusion, this study shows that taking advantage of or triggering cell proliferation, specifically DNA replication in S-phase, may serve as an important tool to improve efficiency of CRISPR/Cas9-mediated genome editing in the liver and provide a curative therapy for IEMs in both children and adults.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36258038     DOI: 10.1038/s41434-022-00369-8

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   4.184


  41 in total

1.  Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses.

Authors:  N D Tran; C D Porada; G Almeida-Porada; H A Glimp; W F Anderson; E D Zanjani
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 2.  Genetic therapies for the fetus.

Authors:  Alan W Flake
Journal:  Clin Obstet Gynecol       Date:  2002-09       Impact factor: 2.190

3.  Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer.

Authors:  Christopher D Porada; Paul J Park; Graça Almeida-Porada; Wansheng Liu; Ferhat Ozturk; Hudson A Glimp; Esmail D Zanjani
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

Review 4.  Immune responses to AAV in clinical trials.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

5.  In utero gene editing for monogenic lung disease.

Authors:  Deepthi Alapati; William J Zacharias; Heather A Hartman; Avery C Rossidis; John D Stratigis; Nicholas J Ahn; Barbara Coons; Su Zhou; Hiaying Li; Kshitiz Singh; Jeremy Katzen; Yaniv Tomer; Alexandra C Chadwick; Kiran Musunuru; Michael F Beers; Edward E Morrisey; William H Peranteau
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

Review 6.  Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.

Authors:  F Endo; M S Sun
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

Review 7.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

8.  Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.

Authors:  Caitlin VanLith; Rebekah Guthman; Clara T Nicolas; Kari Allen; Zeji Du; Dong Jin Joo; Scott L Nyberg; Joseph B Lillegard; Raymond D Hickey
Journal:  Hum Gene Ther       Date:  2018-06-22       Impact factor: 5.695

9.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  In utero CRISPR-mediated therapeutic editing of metabolic genes.

Authors:  Avery C Rossidis; John D Stratigis; Alexandra C Chadwick; Heather A Hartman; Nicholas J Ahn; Haiying Li; Kshitiz Singh; Barbara E Coons; Li Li; Wenjian Lv; Philip W Zoltick; Deepthi Alapati; William Zacharias; Rajan Jain; Edward E Morrisey; Kiran Musunuru; William H Peranteau
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.